Please assess the completion status of the following clinical trial:

Trial Title: Safety and Efficacy of Evolocumab in Combination With Statin Therapy in Adults With Diabetes and Hyperlipidemia or Mixed Dyslipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: QUADRUPLE
- Phase: PHASE3
- Number of Arms: 4.0

Eligibility Criteria:
Inclusion Criteria:~* Males and females with type 2 diabetes (receiving pharmacologic treatment for at least 6 months or longer) with stable diabetes therapy~* Lipid-lowering therapy must be unchanged for at least 4 weeks or more~* Subjects receiving statin therapy at screening must have a fasting LDL-C of greater than or equal to 100 mg/dL~* Subjects not receiving statin therapy at screening must have a fasting LDL-C of greater than or equal to 130 mg/dL~Exclusion criteria:~* New York Heart Association (NYHA) class III or IV heart failure~* Uncontrolled cardiac arrhythmia~* Uncontrolled hypertension~* Type 1 diabetes or poorly controlled type 2 diabetes~* Uncontrolled hypothyroidism or hyperthyroidism.

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: 80 Years
- Healthy Volunteers: f

Study Arms:
- Atorvastatin (Q2W) (Type: ACTIVE_COMPARATOR): Participants received placebo subcutaneous injection once every 2 weeks (Q2W) and 20 mg atorvastatin orally once a day for up to 12 weeks.
- Atorvastatin (QM) (Type: ACTIVE_COMPARATOR): Participants received placebo subcutaneous injection once a month (QM) and 20 mg atorvastatin orally once a day for up to 12 weeks.
- Evolocumab Q2W + Atorvastatin (Type: EXPERIMENTAL): Participants received 140 mg evolocumab by subcutaneous injection once every 2 weeks and 20 mg atorvastatin orally once a day for up to 12 weeks.
- Evolocumab QM + Atorvastatin (Type: EXPERIMENTAL): Participants received 420 mg evolocumab by subcutaneous injection once a month and 20 mg atorvastatin orally once a day for up to 12 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).